Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06117046
PHASE4

The Cardio-protective Effect of Cardiomyopeptidin on Myocardial Injury in ICU Patients With Non-organic Heart Disease: a Prospective, Randomized Controlled Pilot Study

Sponsor: Nanfang Hospital, Southern Medical University

View on ClinicalTrials.gov

Summary

The study was a single-center, randomized controlled pilot study. To explore the cardioprotective effect of cardiopeptidin on non-heart disease patients with severe cardiac injury by comparing whether cardiopeptidin was used.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

234

Start Date

2023-02-27

Completion Date

2023-11-25

Last Updated

2026-09-17

Healthy Volunteers

No

Interventions

DRUG

Cardiopeptidin

Cardiopeptidin was administered intravenously once a day with cardiopeptidin for 3 days.The dosing regimen follows the recommended dosage of 1 mg/kg/day as outlined in the product manual, with doses calculated based on the ideal body weight.

DRUG

50 ml of normal saline intravenous infusion

50 ml of normal saline intravenous infusion

Locations (1)

Southern medical university Nanfang hospital

Guangzhou, China